Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Net Cash Flow (2021 - 2025)

ARS Pharmaceuticals' Net Cash Flow history spans 5 years, with the latest figure at -$18.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 263.44% year-over-year to -$18.2 million; the TTM value through Dec 2025 reached -$9.5 million, up 52.86%, while the annual FY2025 figure was -$9.5 million, 52.86% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$18.2 million at ARS Pharmaceuticals, down from $8.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $173.2 million in Q4 2022 and bottomed at -$122.7 million in Q1 2023.
  • The 5-year median for Net Cash Flow is -$7.7 million (2022), against an average of $839800.0.
  • The largest YoY upside for Net Cash Flow was 508.91% in 2023 against a maximum downside of 1461.7% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $121.5 million in 2021, then surged by 42.61% to $173.2 million in 2022, then plummeted by 93.97% to $10.4 million in 2023, then increased by 6.91% to $11.2 million in 2024, then tumbled by 263.44% to -$18.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Net Cash Flow are -$18.2 million (Q4 2025), $8.0 million (Q3 2025), and $11.7 million (Q2 2025).